- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04234022
Zn-DDC to Target Hypoxia-NFkappaB-CSCs Pathway in Multiple Myeloma
Zn-DDC to Target Hypoxia-NFkappaB-CSCs Pathway and Improve the Treatment Outcomes of Haematological Malignancies - A Translation Bench Study
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Up to 60 myeloma bone marrow samples from Myeloma patients and 10 bone marrow samples from other haematological malignancy samples (Acute leukaemia's) at Diagnosis and Relapse will be tested.
Patients attending haematology clinics at New Cross Hospital will be reviewed for eligibility of the study by the clinician and if they meet the recruitment criteria, they will be approached to participate at clinic.
After informed consent, participants will be asked to donate an additional 2-3ml sample of bone marrow in a single aliquot for the purpose of this study whilst undergoing a bone marrow aspirate as part of their routine clinical care at diagnosis and relapse.The single aliquot will be sent to the University of Wolverhampton for analysis.
Specific clincial data will be collected at the time of diagnosis and relapse:
- Diagnosis
- Date diagnosed
- Disease stage
- Relapse status
- Age
- Sex
- Previous treatments
- Date of marrow sample
- Marrow trephine
- Marrow liquid The clinical data set will remain at The Royal Wolverhampton NHS Trust whilst analysis of the samples takes place. Once the samples have been analysed, the clinical data will then be released to determine relapsed or refractory disease and correlation with the in vitro data.
Study Type
Enrollment (Estimated)
Contacts and Locations
Study Contact
- Name: Supratik Basu
- Phone Number: 01902307999
- Email: supratik.basu@nhs.net
Study Contact Backup
- Name: Lorraine Jacques
- Phone Number: 01902695065
- Email: lorraine.jacques@nhs.net
Study Locations
-
-
-
Wolverhampton, United Kingdom, WV10 0QP
- Recruiting
- The Royal Wolverhampton NHS Trust
-
Contact:
- Supratik Basu
- Email: supratik.basu@nhs.net
-
Contact:
- Lucy Stelfox
- Email: lucy.stelfox@nhs.net
-
Principal Investigator:
- Supratik Basu
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Sampling Method
Study Population
Description
Inclusion Criteria:
- Patients diagnosed with haematological malignancy - either myeloma or acute leukaemia
- Patients must be 18 years or over
- Patients must be willing and able to give informed consent
Exclusion Criteria:
- Pregnant patients will not be entered
Study Plan
How is the study designed?
Design Details
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
---|---|
Zn-DDC
samples to be exposed with Zn-DDC (Imuthiol) alone
|
Zn-DDC added to myeloma samples for culturing
|
Lenalidomide with Zn-DDC
samples to be exposed with Lenalidomide in combination with Zn-DDC
|
Lanalidomide with Zn-DDC added to myeloma samples for culturing
|
Pomalidomide with Zn-DDC
samples to be exposed with Pomalidomide in combination with Zn-DDC
|
Lanalidomide with Zn-DDC added to myeloma samples for culturing
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Imuthiol and zinc efficacy
Time Frame: 7 days
|
examine the cyctotoxicity of Imuthiol and zinc in combination with other drugs
|
7 days
|
Cell kill and determination of IC50 (inhibitory concentration) and apoptotic pathways involved
Time Frame: 7 days
|
Cell kill and determination of IC50 (inhibitory concentration) and apoptotic pathways involved
|
7 days
|
Collaborators and Investigators
Collaborators
Investigators
- Principal Investigator: Supratik Basu, The Royal Wolverhampton NHS Trust
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Cardiovascular Diseases
- Vascular Diseases
- Immune System Diseases
- Neoplasms by Histologic Type
- Neoplasms
- Lymphoproliferative Disorders
- Immunoproliferative Disorders
- Hematologic Diseases
- Hemorrhagic Disorders
- Hemostatic Disorders
- Paraproteinemias
- Blood Protein Disorders
- Signs and Symptoms, Respiratory
- Multiple Myeloma
- Neoplasms, Plasma Cell
- Hypoxia
- Physiological Effects of Drugs
- Antineoplastic Agents
- Immunologic Factors
- Angiogenesis Inhibitors
- Angiogenesis Modulating Agents
- Growth Substances
- Growth Inhibitors
- Pomalidomide
Other Study ID Numbers
- 2019HAE109
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Multiple Myeloma
-
Lawson Health Research InstituteThe Ottawa Hospital; Hamilton Health Sciences Corporation; Dalhousie University; Niagara Health SystemActive, not recruitingMultiple Myeloma in Relapse | Multiple Myeloma With Failed Remission | Multiple Myeloma Stage I | Multiple Myeloma Progression | Multiple Myeloma Stage II | Multiple Myeloma Stage IIICanada
-
National Cancer Institute (NCI)Active, not recruitingSmoldering Multiple Myeloma | Refractory Multiple Myeloma | DS Stage I Multiple Myeloma | DS Stage II Multiple Myeloma | DS Stage III Multiple MyelomaUnited States
-
Fred Hutchinson Cancer Research Center/University...National Cancer Institute (NCI)CompletedStage I Multiple Myeloma | Stage II Multiple Myeloma | Stage III Multiple Myeloma | Refractory Multiple MyelomaUnited States
-
Case Comprehensive Cancer CenterNational Cancer Institute (NCI)TerminatedStage I Multiple Myeloma | Stage II Multiple Myeloma | Stage III Multiple Myeloma | Refractory Multiple MyelomaUnited States
-
Mayo ClinicCompletedMultiple Myeloma | Stage I Multiple Myeloma | Stage II Multiple Myeloma | Stage III Multiple Myeloma | Refractory Multiple MyelomaUnited States
-
National Cancer Institute (NCI)TerminatedStage I Multiple Myeloma | Stage II Multiple Myeloma | Stage III Multiple Myeloma | Refractory Multiple MyelomaUnited States
-
National Cancer Institute (NCI)CompletedStage I Multiple Myeloma | Stage II Multiple Myeloma | Stage III Multiple Myeloma | Refractory Multiple MyelomaUnited States
-
City of Hope Medical CenterCompletedStage I Multiple Myeloma | Stage II Multiple Myeloma | Stage III Multiple Myeloma | Refractory Multiple MyelomaUnited States
-
University of WashingtonNational Cancer Institute (NCI)TerminatedStage I Multiple Myeloma | Stage II Multiple Myeloma | Stage III Multiple Myeloma | Refractory Multiple MyelomaUnited States
-
Fred Hutchinson Cancer CenterNational Cancer Institute (NCI)CompletedStage I Multiple Myeloma | Stage II Multiple Myeloma | Stage III Multiple Myeloma | Refractory Multiple MyelomaUnited States
Clinical Trials on Zn-DDC
-
OHSU Knight Cancer InstituteOregon Health and Science UniversityWithdrawnAnatomic Stage IV Breast Cancer AJCC v8 | Metastatic Triple-Negative Breast Carcinoma | Stage III Fallopian Tube Cancer AJCC v8 | Stage III Ovarian Cancer AJCC v8 | Stage III Primary Peritoneal Cancer AJCC v8 | Stage IV Fallopian Tube Cancer AJCC v8 | Stage IV Ovarian Cancer AJCC v8 | Stage IV Primary... and other conditionsUnited States
-
K-Group Alpha, Inc., a wholly owned subsidiary...RecruitingAcute Myeloid Leukemia (AML)United States
-
Coloplast A/SCompletedIntermittent Urethral CatheterizationDenmark
-
Zentera Therapeutics HK LimitedCompleted
-
Zeno Alpha Inc.Completed
-
Zentera Therapeutics HK LimitedTerminated
-
University of Colorado, DenverNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); International... and other collaboratorsCompletedMicronutrient DeficienciesUnited States, Kenya
-
University of Colorado, DenverInternational Centre for Diarrhoeal Disease Research, BangladeshCompletedEnvironmental Enteric Dysfunction | Zinc DeficiencyUnited States, Bangladesh
-
Suzhou Zanrong Pharma LimitedRecruitingAdvanced Solid Tumors | HER2-positive Breast CancerChina
-
Suzhou Zanrong Pharma LimitedRecruitingAdvanced Solid Tumors | HER2-positive Breast CancerUnited States